ArticleFrontiers in physiology2018
A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury.
Article in Frontiers in physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Zingerone as a Neuroprotective Agent Against Cognitive Disorders: A Systematic Review of Preclinical Studies.International journal of molecular sciences · 2025Pooled it
- Clinical and Preclinical Systematic Review ofFrontiers in pharmacology · 2020Pooled it
- A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics onInternational journal of molecular sciences · 2019Pooled it
- Targeting Telomere Shortening in Vascular Aging and Atherosclerosis: Therapeutic Promise ofJournal of cardiovascular development and disease · 2025Review
- Therapeutic potential and mechanistic insights of astragaloside IV in the treatment of arrhythmia: a comprehensive review.Frontiers in pharmacology · 2025Review
- Total biosynthesis of the medicinal triterpenoid saponin astragalosides.Nature plants · 2024Article
- Inflammation and coronary microvascular disease: relationship, mechanism and treatment.Frontiers in cardiovascular medicine · 2024Review
- Exploratory review on the effect ofFrontiers in pharmacology · 2024Review
- Astragaloside IV attenuates cardiac hypertrophy in rats born from mothers with intrauterine hypoxia through the PKCβII/Egr‑1 pathway.Experimental and therapeutic medicine · 2023Article
- Natural compounds regulate the PI3K/Akt/GSK3β pathway in myocardial ischemia-reperfusion injury.Cell cycle (Georgetown, Tex.) · 2023Article
- Advances in Chemical Composition, Extraction Techniques, Analytical Methods, and Biological Activity ofMolecules (Basel, Switzerland) · 2022Review
- Traditional Chinese Medicine Shen-Yuan-Dan (SYD) Improves Hypoxia-Induced Cardiomyocyte Apoptosis in Neonatal Rats by Upregulating miR-24/Bim Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?Frontiers in cardiovascular medicine · 2021Review
- Editorial: Traditional Chinese Medicine: Organ Vascular Injury - Volume II.Frontiers in physiology · 2021Article
- The protective effects of different compatibility proportions of the couplet medicines for Astragali Radix andPharmaceutical biology · 2020Article
- Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a.Molecular and cellular biochemistry · 2020Article
- The Role of Endophytic/Epiphytic Bacterial Constituents in the Immunostimulatory Activity of the Botanical,The Yale journal of biology and medicine · 2020Article
- Astragaloside IV alleviates myocardial ischemia-reperfusion injury in rats through regulating PI3K/AKT/GSK-3β signaling pathways.Acta cirurgica brasileira · 2019Article
- Qiliqiangxin Capsule Improves Cardiac Function and Attenuates Cardiac Remodeling by Upregulating miR-133a after Myocardial Infarction in Rats.Evidence-based complementary and alternative medicine : eCAM · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragaloside IV (AS-IV), the major pharmacological extract from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.